Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
100%
Disease
29%
Botulinum Toxin A
21%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
20%
Cerebral Palsy
19%
Tuberous Sclerosis
19%
Adverse Event
14%
Autoimmune Disease
14%
Placebo
13%
Clinical Trial
12%
Spasticity
12%
Prevalence
10%
Natalizumab
9%
Subependymal Giant Cell Astrocytoma
9%
Carbamazepine
9%
Everolimus
9%
Beta Interferon
8%
Glatiramer
8%
Immunosuppressive Agent
7%
Glioblastoma
7%
Myelooptic Neuropathy
7%
Neoplasm
6%
Monoclonal Antibody
6%
Pes equinus
5%
Angiomyolipoma
5%
Clinical Study
5%
Combination Therapy
5%
Pharmacotherapy
5%
Disease Exacerbation
5%
Fingolimod
5%
Teriflunomide
5%
Atorvastatin
5%
Alemtuzumab
5%
Neuroscience
Multiple Sclerosis
72%
Natalizumab
22%
Cerebral Palsy
16%
Tuberous Sclerosis
12%
Holoprosencephaly
11%
Epidermal Growth Factor Receptor
11%
Central Nervous System
11%
T Cell
10%
Progressive Multifocal Leukoencephalopathy
8%
Functional near Infrared Spectroscopy
8%
Adverse Effect
8%
Neuromyelitis Optica
8%
Peripheral Nerve
7%
Treatment of Multiple Sclerosis
7%
B Cell
7%
Relapsing Remitting Multiple Sclerosis
6%
Astrocytoma
6%
Statin
6%
Experimental Autoimmune Encephalomyelitis
6%
Beta Interferon
5%
Autoimmune Disease
5%
Magnetic Resonance Imaging
5%
Rituximab
5%
Keyphrases
Multiple Sclerosis
49%
Multiple Sclerosis Treatment
18%
Natalizumab
14%
Statins
12%
Central Nervous System
12%
Neuromyelitis Optica
9%
Tuberous Sclerosis Complex
9%
Cerebral Palsy children
8%
Interferon-β (IFN-β)
7%
Cerebrospinal Fluid
6%
B Cells
6%
Autoimmune Disease
6%
Holoprosencephaly
6%
Subependymal Giant Cell Astrocytoma
6%
Glatiramer Acetate
6%
Relapsing-remitting multiple Sclerosis
5%
Mechanism of Action
5%
Mitoxantrone
5%